Inhibition of Β1 integrin and IL-3RΒ common subunit interaction hinders tumour angiogenesis

Oncogene

Volumn 29, Issue 50, 2010, Pages 6581-6590

  Uberti, B ^a   Dentelli, P ^a   Rosso, A ^a   Defilippi, P ^b   Brizzi, M F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

1 integrin; endothelial progenitor cells; IL 3; IL 3 receptor; tumour angiogenesis

Indexed keywords

BETA1 INTEGRIN; CD131 ANTIGEN; FUSION PROTEIN FC1.3; FUSION PROTEIN FC1.4; FUSION PROTEIN FC4; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL EXPANSION; CELL FATE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MORPHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; STEM CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADULT; ANIMALS; ANTIGENS, CD29; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERLEUKIN-3; MALE; MICE; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS; STEM CELLS;

MURINAE;

EID: 78650305331     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.384     Document Type: Article

References (45)

1. Ahn GO, Brown JM. (2009). Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 12: 159-164.
2. Asahara T, Murohara T, SulliVan A, Silver M, Van der Zee R, Li T et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967.
3. Bazan JF. (1990). Haemopoietic receptors and helical cytokines. Immunol Today 11: 350-354.
4. Bellik L, Ledda F, Parenti A. (2005). Morphological and phenotypical characterization of human endothelial progenitor cells in an early stage of differentiation. FEBS Lett 579: 2731-2736.
5. Biancone L, Stamenkovic I, Cantaluppi V, Boccellino M, De Martino A, Bussolino F et al. (1999). Expression of L-selectin ligands by transformed endothelial cells enhances T cell-mediated rejection. J Immunol 162: 5263-5269.
6. Brizzi MF, Battaglia E, Montrucchio G, Dentelli P, Del Sorbo L, Garbarino G et al. (1999). Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 84: 785-796.
7. Buitenhuis M, Coffer PJ, Koenderman L. (2004). Signal transducer and activator of transcription 5 (STAT5). Int J Biochem Cell Biol 36: 2120-2124.
8. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. (2003). Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 17: 1159-1161.
9. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA et al. (2001). Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 104: 291-300.
10. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M et al. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8: 211-226.
11. Defilippi P, Rosso A, Dentelli P, Calvi C, Garbarino G, Tarone G et al. (2005). {Beta}1 Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation. J Cell Biol 168: 1099-1108.
12. Dentelli P, Del Sorbo L, Rosso A, Molinar A, Garbarino G, Camussi G et al. (1999). Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation. J Immunol 15: 2151-2159.
13. Dentelli P, Rosso A, Balsamo A, Colmenares Benedetto S, Zeoli A et al. (2007). C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothe-lium. Blood 109: 4264-4271.
14. Dentelli P, Rosso A, Calvi C, Ghiringhello B, Garbarino G, Camussi G et al. (2004). IL-3 affects endothelial cell-mediated smooth muscle cell recruitment by increasing TGF beta activity: potential role in tumor vessel stabilization. Oncogene 23: 1681-1692.
15. Dentelli P, Rosso A, Garbarino G, Calvi C, Lombard E, Di Stefano P et al. (2005). The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovasculariza-tion. Oncogene 24: 6394-6405.
16. Desgrosellier JS, Cheresh DA. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
17. Folkman J. (2006). Angiogenesis. Annu Rev Med 57: 1-18.
18. Furuya M, Yonemitsu Y, Aoki I. (2009). III. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des 15: 1854-1867.
19. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N et al. (2009). Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796: 33-40.
20. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. (2008). Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198.
21. Giancotti FG, Tarone G. (2003). Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 19: 173-206.
22. Giraudo E, Arese M, Toniatti C, Strasly M, Primo L, MantoVani A et al. (1996). IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells. J Immunol 157: 2618-2623.
23. Groger M, Loewe R, Holnthoner W, Embacher R, Pillinger M, Herron GS et al. (2004). IL-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol 173: 7161-7169.
24. Guo W, Giancotti FG. (2004). Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816-826.
25. Hutchings H, Ortega N, Plouet J. (2003). Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 17: 1520-1522.
26. Kibbey MC, Grant DS, Klieinman HK. (1992). Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo Matrigel model. J Natl Cancer Inst 84: 1633.
27. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
28. Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K et al. (2005). PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19: 397-410.
29. Mui AL, Wakao H, Harada N, O'Farrell AM, Miyajima A. (1995). Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol 57: 799-803.
30. Naldini A, Carraro F. (2005). Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 4: 3-8.
31. Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S et al. (2007). Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 21: 1546-1558.
32. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ. (1995). T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 92: 6547-6551.
33. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC et al. (2005). Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11: 261-262.
34. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. (2002). Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2: 826-835.
35. Reddy EP, Korapati A, Chaturvedi P, Rane S. (2000). IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19: 2532-2547.
36. Schroeter MR, Leifheit M, Sudholt P, Heida NM, Dellas C, Rohm I et al. (2008). Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res 103: 536-544.
37. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M et al. (2008). Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangio-genic drugs as chemosensitizing agents. Cancer Cell 14: 263-273.
38. Shaked Y, Kerbel RS. (2007). Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67: 7055-7058.
39. Shojaei F, Ferrara N. (2008). Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 11: 219-230.
40. Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE. (2008). Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 28: 1703-1713.
41. Streuli CH, Akhtar N. (2009). Signal co-operation between integrins and other receptor systems. Biochem J 18: 491-503.
42. Tavernier J, Devos R, Cornelis S, Tuypens T, Van der Heyden J, Fiers W et al. (1991). A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 66: 1175-1184.
43. Togliatto G, Trombetta A, Dentelli P, Baragli A, Rosso A, Granata R et al. (2010). Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 59: 1016-1025.
44. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG et al. (1995). A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phos-phorylated interleukin 3 and erythropoietin receptors. EMBO J 14: 2816-2826.
45. Zeoli A, Dentelli P, Rosso A, Togliatto G, Trombetta A, Damiano L et al. (2008). Interleukin-3 promotes expansion of hemopoietic-derived CD45+ angiogenic cells and their arterial commitment via STAT5 activation. Blood 112: 350-361.